Nicholas Segal Net Worth

The estimated Net Worth of Nicholas Segal is at least $3.29 Million dollars as of 26 March 2014. Nicholas Segal owns over 215,298 units of TherapeuticsMD Inc stock worth over $401,466 and over the last 13 years Nicholas sold TXMD stock worth over $2,884,993.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Nicholas Segal TXMD stock SEC Form 4 insiders trading

Nicholas has made over 4 trades of the TherapeuticsMD Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Nicholas sold 215,298 units of TXMD stock worth $1,442,497 on 26 March 2014.

The largest trade Nicholas's ever made was selling 215,298 units of TherapeuticsMD Inc stock on 26 March 2014 worth over $1,442,497. On average, Nicholas trades about 25,167 units every 9 days since 2012. As of 26 March 2014 Nicholas still owns at least 225,809 units of TherapeuticsMD Inc stock.

You can see the complete history of Nicholas Segal stock trades at the bottom of the page.

What's Nicholas Segal's mailing address?

Nicholas's mailing address filed with the SEC is 6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON, FL, 33487.

Insiders trading at TherapeuticsMD Inc

Over the last 13 years, insiders at TherapeuticsMD Inc have traded over $21,656,853 worth of TherapeuticsMD Inc stock and bought 721,732 units worth $2,299,099 . The most active insiders traders include Cooper C. Collins, Brian Bernick und Robert G Finizio. On average, TherapeuticsMD Inc executives and independent directors trade stock every 29 days with the average trade being worth of $272,607. The most recent stock trade was executed by John C.K. Iv Milligan on 25 October 2019, trading 72,000 units of TXMD stock currently worth $198,000.

What does TherapeuticsMD Inc do?

therapeuticsmd, inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their health care issues. we create products to address the unique changes and challenges women experience through every stage of their lives. with momentum fueled by the needs of our customers, we combine entrepreneurial spirit and clinical expertise to develop innovative solutions designed to go beyond what is presently available. this includes a variety of therapies in our pipeline, along with prescription prenatal vitamins under the vitamedmd® and bocagreenmd® brands. see our community guidelines: https://www.therapeuticsmd.com/social-media-community-guidelines

Complete history of Nicholas Segal stock trades at TherapeuticsMD und TherapeuticsMD Inc

TherapeuticsMD Inc executives and stock owners

TherapeuticsMD Inc executives and other stock owners filed with the SEC include:

• John Milligan,
  President, Secretary
• Brian Bernick,
  Co-Founder
• Robert Finizio,
  Chief Executive Officer and Director
• Robert G. Finizio,
  Co-Founder & Vice Chair
• Mitchell Krassan,
  Chief Strategy and Performance Officer
• John C. K. Milligan IV,
  Chief Exec. Officer of VitaCare Prescription Services
• Michael Donegan,
  Vice President - Finance
• Tommy Thompson,
  Independent Chairman of the Board
• Cooper Collins,
  Independent Director
• J. Martin Carroll,
  Independent Director
• Angus Russell,
  Independent Director
• Jules Musing,
  Independent Director
• Dr. Brian A. Bernick,
  Co-Founder & Chief Scientific Officer
• Nichol Ochsner,
  Vice President, Investor Relations
• Gail Naughton,
  Independent Director
• Karen Ling,
  Independent Director
• Paul Bisaro,
  Independent Director
• Bharat Warrier,
  Chief Manufacturing Officer
• Sebastian Mirkin,
  Chief Medical Officer
• Dawn Halkuff,
  Chief Commercial Officer
• Marlan Walker,
  General Counsel
• John Knighton,
  Chief Compliance Officer
• Adam Miller,
  Chief Information Officer
• James D'Arecca,
  Chief Financial Officer
• Julia M. Amadio,
  Chief Product Officer
• Mitchell L. Krassan,
  Exec. VP and Chief Strategy & Performance Officer
• Chris Gish,
  Sr. VP of Sales
• Michael Donegan,
  Chief Accounting Officer & VP of Fin.
• James C. D'Arecca,
  Chief Financial Officer
• Hugh O'Dowd M.B.A.,
  Pres, CEO & Director
• Robert V Jr La Penta,
  Director
• Nicholas Segal,
  Director
• Jane F Barlow,
  Director
• Daniel A Cartwright,
  Chief Financial Officer
• Randall S Stanicky,
  Director
• Samuel A Greco,
  Director